This inventor holds 1 USPTO granted patent. Top assignee: Bioinvent International Ab. Active years: 2014.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2014
Title: The Innovations of Bjorn Frendéus: Pioneering Biological Materials
Introduction: Bjorn Frendéus, a dedicated inventor from Landskrona, Sweden, has made significant contributions to the field of biotechnology. With one patent to his name, his innovative work focuses on binding molecules that have the potential to transform treatments in medicine.
Latest Patents: Frendéus holds a patent titled "Biological materials and uses thereof." This invention introduces binding molecules, including antibody molecules, that selectively bind to cell surface antigens of target cells. Upon binding, these molecules induce apoptosis, or programmed cell death, in those target cells. Additionally, the patent includes methods, pharmaceutical compositions for apoptosis induction, and their various uses, showcasing a promising area of research with important medical implications.
Career Highlights: Bjorn Frendéus works at Bioinvent International AB, where he engages in groundbreaking research and development in the biotech industry. His role within the company allows him to explore innovative solutions and contribute to advancements that could potentially impact healthcare positively.
Collaborations: In his endeavors, Frendéus collaborates with his coworker Roland Carlsson. Together, they embody the spirit of teamwork and innovation, working towards common goals in the pursuit of new biomedical discoveries.
Conclusion: Bjorn Frendéus exemplifies the innovative spirit that drives biotechnology forward. His patent on binding molecules for apoptosis induction highlights the potential for significant advancements in medical treatments. As he continues to collaborate and develop new ideas at Bioinvent International AB, the impact of his work on the pharmaceutical landscape can be anticipated with great interest.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile